

Current as of September 20, 2023

### Short Talks Selected from Proffered Abstracts

PR-01 **Beta-adrenergic blockade licenses the use of immunotherapy in primary brain tumors and brain metastases.** Selena Lorrey. Duke University, Durham, NC, United States.

PR-02 **Uncovering novel therapeutic avenues for glioma by exploring the functional interplay of FGFR1, p53, and ribosome biogenesis.** Mikael Lindström. Karolinska Institutet, Stockholm, Sweden.

PR-03 **In vivo genome-wide CRISPR/Cas9 screens conducted in an immunocompetent mouse model of glioblastoma identify novel in vivo tumor liabilities and potential mechanisms of resistance to chimeric antigen receptor T-cell (CAR-T) therapy.** Catherine Koch. MIT and HMS, Boston, MA, United States.

PR-04 **Targeting EPHB2/ABL1 restores anti-tumor immunity in a preclinical model of ependymoma.** Taylor Uccello. Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

PR-05 **CAR T-cell motility response to interstitial fluid flow and tumor microenvironment.** Gabriela Geraldo Mendes. Virginia Tech, Roanoke, VA, United States.


PR-06 **Brain metastases roadmap reveals conserved regulatory dynamics rooted in dormant tumor cells.** Remi Klotz. University of Maryland School of Medicine, Baltimore, MD, United States.

PR-07 **H3.3K27M diffuse midline gliomas are sensitive to SWI/SNF chromatin remodeler degradation.** Mateus Mota. University of Michigan, Ann Arbor, MI, United States.

PR-08 **Modeling epigenetic lesions that cause gliomas.** Gilbert Rahme. Dana-Farber Cancer Institute, Boston, MA, United States.

PR-09 **Associations between PM 2.5, vegetation density and childhood brain tumors: a case-control registry-based study from Texas 1995-2011.** Lindsay Williams. University of Minnesota, Minneapolis, MN, United States.

PR-10 **Asc1lb progenitor-specific RB conditional inactivation in zebrafish models rare CNS primitive neuroectodermal tumors.** Maura McGrail. Iowa State University, Ames, IA, United States.



AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN

**AACR**  
American Association  
for Cancer Research

2302033E

Emerging Molecular Targets

**A001 Silencing of EYA4 regulates stemness in H3K27M-mutant diffuse midline glioma.** Ivana Barravecchia. University of Michigan, Ann Arbor, MI, United States.

**A002 MALT1 as a regulator of tumor progression in H3K27-altered diffuse midline glioma.** Hannah Butterfield. University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

**A003 In vitro and in vivo CRISPR screens identify the ubiquitin E3 ligase RBBP6 as a targetable dependency of glioblastoma stem cells.** Qi Xie. Westlake University, Hangzhou, China.

**A004 GTP signaling links metabolism, DNA repair, and responses to genotoxic stress.** Weihua Zhou. University of Michigan, Ann Arbor, MI, United States.

**A006 Reckless mitotic entry as a novel chemosensitization approach for alkylating agents.** Fengchao Lang. NCI, Bethesda, MD, United States.

**A007 Uncovering novel therapeutic avenues for glioma by exploring the functional interplay of FGFR1, p53, and ribosome biogenesis.** Mikael Lindström. Karolinska Institutet, Stockholm, Sweden.


**A008 Disruption of SLFN5 enhances vulnerability to APR-246, a mutant p53 reactivator in glioblastoma.** Ricardo Perez. Northwestern University-RHLCCC, Chicago, IL, United States.

**A009 Plinabulin, a novel tubulin targeting agent, collapses the tumor microtubule network in primary and recurrent patient derived glioblastoma cell lines to inhibit neurosphere invasion and survival.** Kathryn Eisenmann. University of Toledo College of Medicine, Toledo, OH, United States.

**A010 Prostate-Specific Membrane Antigen Use in Glioma Management: Past, Present, and Future.** Neeva Shafii. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States.

**A011 Stopping brain tumors in their tracks- The role of RhoGTPase activating proteins (ARHGAPs) in glioma cell migration and invasion.** Philippa Vaughn-Beaucaire. Brown University, Providence, RI, United States.

**A012 EZH2 as a therapeutic target for glioma.** Lukmanul Hakkim Faruck. Hormel Institute, University of Minnesota, Austin, MN, United States.



AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN

**AACR**  
American Association  
for Cancer Research®

2302033E

**Poster Session A (To be presented on October 20 from 5:30-7:30 p.m. ET)**

Novel Therapeutic Modalities

**A013 Beta-adrenergic blockade licenses the use of immunotherapy in primary brain tumors and brain metastases.** Selena Lorrey. Duke University, Durham, NC, United States.

**A014 ClpP drives efficacy and mediates acquired resistance with imipridones ONC201 and ONC206 in glioma in vitro.** Varun Prabhu. Chimerix, Inc., Durham, NC, United States.

**A015 Predicting Efficacious Drugs and Drug-Biomarker Relationships for Targeted Glioblastoma Treatment.** Danielle Maeser. University of Minnesota, Minneapolis, MN, United States.

**A016 Leveraging synergy of alpha-particle radiotherapy with low levels of chemotherapy to overcome delivery and resistance in treating Glioblastoma.** Aira Sarkar. Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, United States.

**A017 Cell-specific photodynamic therapy for high grade gliomas.** Alberto Arias. CNEA, San Carlos De Bariloche, Argentina.

**A018 Multi-stage, open cranial approaches for resection of primary intracranial neoplasms: a systematic review of the history and current applications.** Nolan Brown. UC Irvine, Newport Beach, CA, United States.

**A019 Phase II trial evaluating the association of peripheral blood immunologic response and therapeutic response to immune checkpoint inhibition in patients with newly diagnosed glioblastoma and gliosarcoma.** Matthew Watowich. Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

**A020 Neural stem cells expressing PTEN-L suppress glioblastoma invasion in vivo.** Ian Lorimer. Ottawa Hospital Research Institute, Ottawa, ON, United States.

**A021 Exosome delivered combinatorial treatment for malignant brain tumors.** Sydney Thomas. University of South Carolina School of Medicine, Columbia, SC, United States.


**A022 Whole Exome Sequencing Reveals Potential Somatic Drivers in Intracranial Epidermoid Cysts (IECs).** Shruthi Kondaboina. University of Washington Medical Center, Seattle, WA, United States.

**A023 Brain penetrant small molecule for the treatment of glioblastoma.** Lilian Patron. Reglgene, Inc., Tucson, AZ, United States.

**A024 Cellular and molecular characterization of cancer stem-like cells isolated from the sub-ventricular zone of glioblastoma patients and treated with Tumor Treating Fields (TTFields).** Yamhilette Licon Munoz. University of New Mexico, Albuquerque, NM, United States.

American Association for Cancer Research Special Conference:

**BRAIN CANCER** | October 19-22, 2023 | Hilton Minneapolis | Minneapolis, Minnesota



AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN

**AACR**  
American Association  
for Cancer Research®

2302033E

**A025 Engineering Messenger RNA Therapies for Brain Tumors.** Saigopalakrishna Yerneni. Carnegie Mellon University, Pittsburgh, PA, United States.

**A026 Evaluation of Evodiamine and Cucurbitacin B as Potential Combination Therapy for Glioblastoma Multifome.** Vrutti Mehta. Long Island University, Brooklyn, NY, United States.

**A027 Feasibility of Diffusing Alpha-emitting Radiotherapy in Orthotopic Glioblastoma Multiforme Murine Tumors and Its Combination With 'Standard-of-care' Drugs in Human Xenografts.** Maayan Vatarescu. Ben-Gurion University of the Negev, Beer-Sheva, Israel, United States.

Other

**A028 Subclonal lineage recording in glioblastoma using CRISPR base editing.** Abigail Marshall. Geisel School of Medicine, Dartmouth College, Lebanon, NH, United States.

**A029 Use and predictors of perceived cognitive function using the Neuro-QoL perceived cognitive function scale in patients with primary brain tumors.** Morgan Johnson. NOB, CCR, NCI, NIH, Bethesda, MD, United States.

**A030 The Montreal Cognitive Assessment (MoCA) administered virtually or via Duo APP in primary brain tumor patients: A preliminary analysis.** McKenzie Kauss. National Institute of Health, Bethesda, MD, United States.

**A031 Prospective and clinical prediction in a retrospective trial that experimentally validated an AI/ML-derived whole-genome predictor as the most accurate and precise predictor of survival and response to treatment in glioblastoma.** Orly Alter. University of Utah, Salt Lake City, UT, United States.

**A032 Preliminary Evaluation of Sleep-Related Patient-Reported Outcomes (PROs), Morningness-Eveningness Chronotype, Objective Sleep Measures Using Smart Wearables in a Primary Brain Tumor Patient Population.** Maeve Pascoe. Neuro-oncology Branch, National Cancer Institute - Center for Cancer Research, National Institutes of Health, Bethesda, MD, United States.

**A033 Murine CNS and bone marrow distribution of the aurora A kinase inhibitor alisertib: Pharmacokinetics and exposure at the sites of efficacy and toxicity.** Juhee Oh. University of Minnesota, Minneapolis, MN, United States.


**A034 A new international programme to accelerate novel therapeutics for brain tumors: Presenting the Brain Tumour Research Novel Therapeutics Accelerator.** Charlotte Aitken. Tessa Jowell Brain Cancer Mission, London, United Kingdom.

**A035 Radiation-induced senescence as a driver of glioblastoma recurrence.** Ben Jordan. UT Health San Antonio, San Antonio, TX, United States.

**A036 Female spouse caregivers of patients with Glioblastoma want better education and communication from health care professionals regarding what to expect during the**

American Association for Cancer Research Special Conference:

**BRAIN CANCER** | October 19-22, 2023 | Hilton Minneapolis | Minneapolis, Minnesota



AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN

**AACR**  
American Association  
for Cancer Research®

2302033E

**disease progression.** Laurie Minns. University of North Carolina Wilmington, Wilmington, NC, United States.

Tumor Immunology and Microenvironment

**A037 The role of tumor microenvironment in metastasis and relapses of medulloblastoma using immunocompetent mouse models.** Niusha Khazaei. McGill University, Montreal, QC, United States.

**A038 Inhibitory Interneuron Loss in Human Glioma Correlates with Reduced Survival, Neuron-Glioma Interactions, and Altered Neural Activity.** Akhil Surapaneni. Dell Medical School at the University of Texas at Austin, Austin, TX, United States.

**A039 In vivo genome-wide CRISPR/Cas9 screens conducted in an immunocompetent mouse model of glioblastoma identify novel in vivo tumor liabilities and potential mechanisms of resistance to chimeric antigen receptor T-cell (CAR-T) therapy.** Catherine Koch. MIT and HMS, Boston, MA, United States.

**A040 The Impact of Antihistamines on the Tumor Microenvironment: Friend or Foe?** Jessica Taylor. CRUK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.

**A041 Vascular normalization improves the delivery and efficacy of CAR-T cells in mouse brain cancers.** Vasiliki Salamei. Massachusetts General Hospital, Boston, MA, United States.

**A042 Targeting EPHB2/ABL1 restores anti-tumor immunity in a preclinical model of ependymoma.** Taylor Uccello. Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

**A043 Pericytes orchestrate a tumor-suppressive microenvironment by impinging on the crosstalk between macrophages and tumor-initiating cells in glioblastoma multiforme.** Sebastian Braun. Lund University, Lund, Sweden.

**A044 Testing Neuro-Oncology Tenets: Are MRI findings and symptoms different with true progression compared with immunotherapy-related treatment effect in patients with primary brain tumors?** Emma Byrne. National Cancer Institute, Bethesda, MD, United States.

**A045 Engineered systems for tumor modeling facilitate the assessment of therapeutic interventions.** Sara Pedron-Haba. University of Illinois Urbana-Champaign, Urbana, IL, United States.

**A046 Exogenous CD200 suppressing T cells is CD200R1 independent.** Zhengming xiong. University of Minnesota, Minneapolis, MN, United States.

**A047 Targeting tumor-myeloid cell symbiosis in glioblastoma.** Peiwen Chen. Northwestern University, CHICAGO, IL, United States.

American Association for Cancer Research Special Conference:

**BRAIN CANCER** | October 19-22, 2023 | Hilton Minneapolis | Minneapolis, Minnesota



AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN


**AACR**  
American Association  
for Cancer Research®

2302033E

**A048 Development and validation of a microfluidic cell culture model for examining cerebral microvascular barrier responses to the tumor microenvironment.** Donald Miller. University of Manitoba and CancerCare Manitoba, Winnipeg, MB, Canada.

**A049 CAR T-cell motility response to interstitial fluid flow and tumor microenvironment.** Gabriela Geraldo Mendes. Virginia Tech, Roanoke, VA, United States.

**A050 Ferritin, associated with worse Overall Survival in recurrent GBM, is reduced by combination of HDACi, ONC206 and radiation.** Vida Tajiknia. Legorreta cancer center, Brown University, Providence, RI, United States.



AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN

**AACR**  
American Association  
for Cancer Research®

2302033E

**Poster Session B (To be presented on October 21 from 4:00-6:00 p.m. ET)**

3D Genomes and Spatial Sequencing

**B001 Glioblastoma evolution and resistance is mediated by a shift in cell state and tumor microenvironmental interactions.** Wajid Al-Holou. University of Michigan, Ann Arbor, MI, United States.

Brain Metastasis

**B002 Circulatory Galectin 3 Binding Protein as a Potential Biomarker in Early Detection of Glioma.** Rashmi Rana. Sir Ganga Ram Hospital, New Delhi, India.

**B003 The OTX2 gene induces tumor growth and triggers leptomeningeal metastasis by regulating the mTOR signaling pathway in medulloblastomas.** Elisabet Ampudia Mesias. University of Minnesota, Minneapolis, MN, United States.

**B004 Clinico-genomic characteristics of breast cancer brain metastasis: A multi-institutional analysis from AACR Project GENIE BPC.** Hannah Fuchs. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

**B005 Lymphoid Aggregates Dictate Immune Activity in Melanoma and Lung Brain Metastases.** Noor Nader. University of Pittsburgh, Pittsburgh, PA, United States.

**B006 Treatment outcome of leptomeningeal metastasis from breast cancer.** Suzy Kim. Seoul National University Boramae Medical Center, Seoul, South Korea.

**B007 Establishment of patient-derived brain metastasis initiating cells as a novel preclinical model of breast cancer metastatization.** Stefania Faletti. Istituto Europeo di Oncologia, Milan, Italy.

**B008 Brain metastases roadmap reveals conserved regulatory dynamics rooted in dormant tumor cells.** Remi Klotz. University of Maryland School of Medicine, Baltimore, MD, United States.

Epigenetics and Epitranscriptomics

**B009 Characterizing the Super Enhancer Landscape of H3K27me3 Loss in MPNST and DIPG.** Christopher Stehn. University of Minnesota, Minneapolis, MN, United States.


**B010 PITAR, a p53 Inactivating TRIM28 associated RNA, executes an alternate way of p53 inactivation.** Kumar Somasundaram. Indian Institute of Science, Bangalore, India.

**B011 Sex-specific chromatin remodelling drives tumorigenesis in glioblastoma.** adham halaoui. UCSD, San Diego, CA, United States.

**B012 H3.3K27M diffuse midline gliomas are sensitive to SWI/SNF chromatin remodeler degradation.** Mateus Mota. University of Michigan, Ann Arbor, MI, United States.

American Association for Cancer Research Special Conference:

**BRAIN CANCER** | October 19-22, 2023 | Hilton Minneapolis | Minneapolis, Minnesota



AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN

**AACR**  
American Association  
for Cancer Research<sup>®</sup>

2302033E

**B013 In vitro stability and in vivo pharmacokinetic behavior of panobinostat in mouse models for the treatment of CNS tumors.** Wenqiu Zhang. University of Minnesota, Minneapolis, MN, United States.

**B014 CHD5 suppresses glioblastoma by inhibiting MYC.** Xueqin Sherine Sun. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.

**B015 RNA N6-methyladenosine (m6A) as a therapeutic target in Diffuse Midline Glioma (DMG).** Samuel Ross. University of Sydney, Sydney, NSW, Australia.

**B016 Targeting the epigenome through combined Facilitates Chromatin Transcription (FACT) and Bromodomain and Extra-Terminal Domain (BET) inhibition in Diffuse Midline Glioma (DMG).** Holly Holliday. Children's Cancer Institute, Sydney, NSW, Australia.

**B017 Modeling epigenetic lesions that cause gliomas.** Gilbert Rahme. Dana-Farber Cancer Institute, Boston, MA, United States.

**B018 Epigenetic targeting improves glioblastoma cell sensitivity to chemotherapy.** Golnaz Asaadi Tehrani. Notre Dame university, South Bend, IN, United States.

Novel Therapeutic Modalities

**B019 A novel repurposed antipsychotic agent for brain cancer acting via the modulation of Akt/FOXO/Bim signaling axis.** Manas Yogendra Agrawal. Texas Tech University Health Sciences Center, Abilene, TX, United States.

**B020 Understanding the role of dNTP pool on double-strand break and resistance to therapy in quiescent hypoxic glioblastoma.** Edidiong Usoro. Augusta University, Augusta, GA, United States.

**B021 Targeting tight junctions at the blood-tumor barrier for improved intratumoral drug delivery in glioblastoma mouse models.** Sean Lawler. Brown University, Providence, RI, United States.

**B022 Interplay Between the Cellular dNTP pool and DNA Double-Strand Break Repair: A Potential Therapeutic Target for Refractory Glioblastoma.** Dominique Monroe. Augusta University, Augusta, GA, United States.

**B023 CNS and systemic pharmacokinetics of antibody-drug conjugate payloads through convection-enhanced delivery.** Jiayan Le. Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, MN, United States.


**B024 New pipeline toward precision therapies for glioblastoma.** Zhi Sheng. Framin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, VA, United States.

**B025 How much is enough? BI-907828: a MDM2-p53 antagonist with limited BBB penetration but potent efficacy in glioblastoma.** Wenjuan Zhang. University of Minnesota, Minneapolis, MN, United States.

American Association for Cancer Research Special Conference:

**BRAIN CANCER** | October 19-22, 2023 | Hilton Minneapolis | Minneapolis, Minnesota





AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN

**AACR**  
American Association  
for Cancer Research<sup>®</sup>

2302033E

**B026 Rotational magnetic drug targeting for leptomeningeal metastases.** Herbert Engelhard. University of Illinois at Chicago, Chicago, IL, United States.

**B027 Repurposing ion channel drugs: the Na<sup>+</sup> channel modifying drug DPI-201-106 significantly enhances the anti-tumor activity of multiple classes of drugs targeting DNA damage repair.** Terrance Johns. Telethon Kids Institute, Perth, WA, United States.

**B028 Systemic and CNS distributional pharmacokinetics of WSD0628, a novel radiosensitizer: Implications for the treatment of brain tumors.** Sneha Rathi. University of Minnesota, Minneapolis, MN, United States.

**B029 A novel lupus-associated antibody that inhibits the growth of aggressive high-grade glioma orthotopic xenografts and enhances radiotherapy via a unique mechanism.** Terrance Johns. Telethon Kids Institute, Perth, WA, United States.

**B030 Synergistic Antitumor Effects of Cold Atmospheric Plasma and Temozolomide in Glioblastoma: Multimodal Approaches Integrating In-Vitro, In Vivo, and In Silico Investigations for Novel and Enhanced Therapeutic Advancements.** Vikas Soni. George Washington University, Washington, United States.

**B031 A brain penetrant Nicotinamide-adenine dinucleotide mimetic impedes *de novo* guanylate synthesis and glioblastoma growth.** Yu-Jung Chen. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

**B032 Designing arrays for the mouse head to facilitate in vivo studies of Tumor Treating Fields (TTFields) treatment of glioblastoma.** Amal El-Mabhouth. Novocure Inc., New York, NY, United States.


Other

**B033 Histone H3.3 K27M and G34R/V glioma driver mutations inhibit mitotic phosphorylation of H3.3 S31, driving tumor formation by inducing chromosomal instability.** Charles Day. University of Minnesota - Hormel Institute, Austin, MN, United States.

**B034 Associations between PM 2.5, vegetation density and childhood brain tumors: a case-control registry-based study from Texas 1995-2011.** Lindsay Williams. University of Minnesota, Minneapolis, MN, United States.

**B035 A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities.** Manav Pathania. University of Cambridge, Cambridge, United States.

**B036 Asc1lb progenitor-specific RB conditional inactivation in zebrafish models rare CNS primitive neuroectodermal tumors.** Maura McGrail. Iowa State University, Ames, IA, United States.



AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN

**AACR**  
American Association  
for Cancer Research<sup>®</sup>

2302033E

**B037 Gene regulatory networks driving developmental origins of Group 3/4 medulloblastoma subtypes.** Piyush Joshi. Deutsches Krebsforschungszentrum, Heidelberg, Germany.

**B038 Accurate Quantitative Profiling of RNA Modifications and Their Associations with Glioblastoma.** Frank Morales Shnaider. University of North Carolina Greensboro, Greensboro, NC, United States.

**B039 Identification of sex-specific molecular features in glioma transcriptome.** Yingbo Huang. University of Minnesota, Minneapolis, MN, United States.

**B040 Former caregivers of patients with glioblastoma multiforme report the Preparedness Assessment for the Transition Home (PATH©) instrument is helpful throughout the disease trajectory.** Elizabeth James. University of North Carolina Wilmington, Durham, NC, United States.

**B041 Biomarkers of neurocognitive functioning: Molecular signatures for cognitive outcomes in a cohort of primary brain tumor patients.** Kaitlynn Slattery. National Institutes of Health, Bethesda, MD, United States.

**B042 A survey of Neuro-Oncology (NOB) Clinical Providers to assess the feasibility and utility of the administration of the Montreal Cognitive Assessment (MoCA) Cognition Duo APP in an Outpatient Clinic.** Madhura Managoli. NOB, CCR, NCI, NIH, Bethesda, MD, United States.

**B043 The Caregiver Burden of Patients with Glioblastoma multiforme (GBM) and Feeling of Regret for Treatment Decisions associated with GBM Standard of Care using Qualitative Analysis.** Marlee Wallace. University of North Carolina at Wilmington, Wilmington, NC, United States.

Tumor Metabolism

**B044 Elongation control of mRNA translation drives Group 3 medulloblastoma adaptation to nutrient deprivation.** Alberto Delaidelli. University of British Columbia, Vancouver, BC, Canada.

**B045 Adaptive purine metabolism drives radiation therapy resistance in H3K27M-diffuse midline glioma.** Erik Peterson. University of Michigan, Ann Arbor, MI, United States.

**B046 Irradiation of patient-derived high-grade gliomas reduces 5-ALA-induced fluorescence utility during re-resection.** Paras Minhas. Stanford University, Palo Alto, CA, United States.

**B047 Inhibition of the polyamine pathway: a novel therapeutic approach to treat aggressive pediatric medulloblastoma.** Aaminah Khan. Children's Cancer Institute, Sydney, NSW, Australia.



AACR Special Conference on  
**Brain Cancer**  
October 19-22, 2023 | Minneapolis, MN

**AACR**  
American Association  
for Cancer Research®

2302033E

**B048 Association between SIRT3 gene polymorphism and increased metabolic rate in brain tumor patients.** Ishrat Mahjabeen. Brown university, providence, RI, United States.

**B049 Uncovering sex-biased immunometabolic roles for NIK in the GBM tumor microenvironment.** Raquel Sitcheran. Texas A&M University School of Medicine, Bryan, TX, United States.

**B050 Metabolic rewiring in human brain cancer.** Daniel Wahl. University of Michigan, Ann Arbor, MI, United States.

**B051 DNA damage signaling activates GTP synthesis to promote glioblastoma treatment resistance.** Andrew Scott. University of Michigan, Ann Arbor, MI, United States.

**B052 Hyaluronic acid influences amino acid metabolism in glioblastoma's U87-MG cell line in a 2D culture via LAT1 transporter expression.** Ashwin Bale. University of Illinois, Urbana Champaign, Urbana, IL, United States.